Genital Herpes Market
- Over the coming decade, the Genital Herpes Treatment Market in the 7MM is poised for notable growth, driven by advancements in research and healthcare practices aimed at enhancing patient outcomes for this prevalent infection
- In 2023, the total Genital Herpes Prevalence across the 7MM was about 225 million of which ~1% of the patients are symptomatic.
- Among all the countries, the United States recorded approximately 1,500,000 cases of symptomatic genital herpes. Germany recorded the highest number of genital herpes cases among the EU4 countries.
- HSV-2 accounted only for ~20% of the total herpes simplex virus cases and are more likely to result in symptomatic genital herpes, including painful genital lesions and flu-like symptoms.
- Approximately 75% of the HSV cases remain undiagnosed due to various factors.
- There are significant unmet needs in the Genital Herpes Therapeutics Market. Although genital herpes is an STI, it significantly impacts the mental and social health of patients along with their sexual health. Also, the diagnostic tests for genital herpes lack accuracy. Another major gap in the Genital Herpes Therapeutics Market is the lack of preventive and curative therapies.
- Currently, antiviral therapy (acyclovir, valacyclovir, famiciclovir) is the most common treatment option available for genital herpes. In 2023, the United States accounted for approximately 50% of the total Genital Herpes Drugs Market across the 7MM.
- The emerging pipeline for genital herpes treatments shows limited strength, with few therapies in development primarily focused on symptom management and recurrence reduction. Consequently, there is a notable absence of preventive or curative treatments among emerging drugs in the current Genital Herpes Drugs Market.
- Rational Vaccines (RVx) was recently awarded USD 2.8 million in National Institute of Health (NIH) funding to help further its research to diagnose, treat, and prevent the spread of the Herpes Simplex Virus (HSV).
Request for Unlocking the CAGR of the Genital Herpes Drugs Market
DelveInsight's “Genital Herpes Drugs Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Genital Herpes Drugs Market report provides real-world prescription pattern analysis, emerging drugs, Genital Herpes Market Share of individual therapies, and historical and forecasted 7MM Genital Herpes market size from 2020 to 2034. The report also covers current Genital Herpes treatment market practices/algorithms and Genital Herpes unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Genital Herpes Treatment Market
Herpes simplex virus (HSV), known as herpes, is a common infection that can cause painful blisters or ulcers. It primarily spreads by skin-to-skin contact. It is treatable but not curable. There are two types of herpes simplex virus. Type 1 (HSV-1) mostly spreads by oral contact and causes infections in or around the mouth (oral herpes or cold sores). It can also cause genital herpes. Most adults are infected with HSV-1. Type 2 (HSV-2) spreads by sexual contact and causes genital herpes.
Most people with herpes have no symptoms or only mild symptoms. Many people aren’t aware they have the infection and can pass along the virus to others without knowing.
Herpes sores usually appear as one or more blisters on or around the genitals, rectum, or mouth. This is known as having an “outbreak”. The blisters break and leave painful sores that may take a week or more to heal. Flu-like symptoms (e.g., fever, body aches, or swollen glands) also may occur during the first outbreak. Symptoms may be different during the first episode (or ‘outbreak’) of infection than during a recurrent episode. If symptoms occur, they often begin with tingling, itching, or burning near where the sores will appear.
Healthcare providers may diagnose genital herpes by simply looking at any sores that are present. Providers can also take a sample from the sore(s) and test it. If sores are not present, a blood test may be used to look for HSV antibodies. HSV nucleic acid amplification tests (NAAT) are the most sensitive and highly specific tests available for diagnosing herpes. However, in some settings, viral culture is the only test available.
A comprehensive report on genital herpes outlines its pathophysiology, diagnostic methodologies, and a detailed treatment protocol, accompanied by a real-world case study illustrating a patient's journey from the onset of symptoms to diagnosis and subsequent treatment.
Genital Herpes Treatment
Genital herpes, while incurable, can be managed effectively with medication to alleviate pain, and itching, and promote faster healing of sores. Antiviral medicines are the primary treatment, reducing symptoms, and contagiousness, and potentially preventing outbreaks when taken regularly. Home remedies like warm sitz baths and wearing cotton underwear can aid in sore healing. Oral antiviral medications such as acyclovir, valacyclovir, and famciclovir offer clinical benefits for episodic treatment or long-term suppression. Though these drugs don't cure the disease, they can significantly improve the condition's management and reduce recurrence. Side effects are rare and generally mild, including nausea, vomiting, headache, and diarrhea.
Genital Herpes Treatment options vary depending on the stage and severity of the infection. For first clinical episodes, antiviral therapy is crucial to alleviate symptoms and speed up recovery, with medications like acyclovir showing significant reductions in viral shedding and lesion healing time. Episodic therapy is suitable for patients with mild and infrequent recurrences, aiming to lessen symptoms and infectivity during outbreaks. Suppressive therapy, recommended for those experiencing more than six episodes per year, significantly reduces recurrences and transmission risk, with acyclovir, valacyclovir, and famciclovir being effective options. In severe cases, IV acyclovir is advised, while maintaining cleanliness and using soothing measures like ice packs can aid in symptom management. Topical acyclovir is less effective and not recommended compared to oral antiviral medication. Regular reassessment is necessary to determine the need for continued therapy.
Genital Herpes Epidemiology
The Genital Herpes epidemiology chapter in the Genital Herpes Drugs Market report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Genital Herpes epidemiology is segmented with detailed insights into Prevalent HSV Infected Cases, Symptomatic Cases of Genital Herpes, Gender-specific Cases of Genital Herpes, Diagnosed Cases of Genital Herpes, Total Recurrent Cases of Genital Herpes, and Treated
Patient Pool of Genital Herpes.
- According to our findings, herpes simplex virus (HSV) infection, commonly known as herpes, is widespread worldwide, affecting nearly 225,567,000 patients in the 7MM in 2023.
- According to DelveInsight's estimates, in 2023, approximately 80% of patients infected with herpes simplex virus have HSV-1 infections in the United States.
- In EU4 and the UK, the total symptomatic cases of genital herpes were around 1,204,000 cases in 2023, and of them, more than 60% were female.
- According to DelveInsight's consultant, in 2023, approximately 482,000 cases out of the total diagnosed genital herpes patient pool in the 7MM are classified as naïve cases.
- As per DelveInsight's estimates, in 2023, the total treated cases for genital herpes in the 7MM were more than 2,430,000 including both naïve and recurrent cases.
Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Genital Herpes Prevalence
Genital Herpes Drugs Market Chapters
The drug chapter segment of the Genital Herpes market report encloses a detailed analysis of Genital Herpes late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Genital Herpes clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Emerging Genital Herpes Drugs
- PRITELIVIR (AIC316): AiCuris
PRITELIVIR, an innovative therapeutic candidate, is undergoing pivotal Phase III trials for treating acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised patients. While immunocompetent individuals commonly experience recurrent labial and genital herpes infections, symptoms are often more severe in immunocompromised patients, leading to disseminated disease, keratitis, and encephalitis. Pritelivir demonstrates dual inhibition of both HSV-1 and HSV-2 replication and has shown promising tolerability and pharmacologic properties in clinical trials.
Notably, it remains effective against viruses resistant to existing drugs, leading to its breakthrough therapy designation by the US FDA.
- HDIT101: Heidelberg ImmunoTherapeutics
HDIT101 is a humanized monoclonal antibody developed for the treatment of herpes simplex virus (HSV) infections. HDIT101 binds to an HSV-1 and HSV-2 common epitope on glycoprotein B which is indispensable for viral infectivity.
A first-in-human study showing the pharmacokinetics, safety, and tolerability of HDIT101 was completed (HDIT101 Phase I). At present, two randomized Phase II studies are currently ongoing in patients with recurrent HSV-2 positive Herpes genitalis (MATCH-2) and patients with orolabial HSV-1 infections (MATCH-1), respectively.
Genital Herpes Market Outlook
Key Genital Herpes Companies, such as AiCuris, Heidelberg ImmunoTherapeutics, BioNTech, and, others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Genital Herpes.
- The Genital Herpes market size in the seven major markets was more than USD 870 million in 2023.
- Among EU4 and the United Kingdom, Germany had the highest Genital Herpes market size, followed by the United Kingdom, and the least Genital Herpes market share was captured by Spain in 2023.
- In the United States, foscarnet garnered the maximum Genital Herpes market share in 2023, accounting for more than 80% of the total drug sales.
- There is a high Genital Herpes unmet need for preventive and curative therapies for managing genital herpes. New antiviral drugs alone or in combination with acyclovir are being developed to help control such infections and to diminish the possibility of resistance.
Genital Herpes Drugs Uptake
This section focuses on the uptake rate of potential Genital Herpes drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key Genital Herpes companies evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Genital Herpes Pipeline Activities
The Genital Herpes pipeline segment provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Genital Herpes companies involved in developing targeted therapeutics.
Pipeline Development Activities
The Genital Herpes pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for Genital Herpes emerging therapies.
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Drugs for Genital Herpes
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving Genital Herpes treatment market landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of the Genital Herpes Treatment Market. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and Genital Herpes treatment market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Genital Herpes Therapeutics Market Access and Reimbursement
Genital herpes, classified as a sexually transmitted infection (STI), manifests through herpetic sores and painful blisters, which can rupture and discharge fluid. To alleviate symptoms and extend symptom-free periods, treatment often involves antiviral medications. Acyclovir, marketed under the brand name ZOVIRAX, stands as a cost-effective option for managing or preventing infections triggered by specific viruses like herpes and shingles. This medication, available in both generic and brand formulations, enjoys widespread use due to its efficacy and affordability. While generic acyclovir is typically covered by most Medicare and insurance plans, individuals may also find competitive prices through pharmacy coupons or cash transactions.
The Genital Herpes drugs market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc
Genital Herpes Treatment Market Report Scope
- The Genital Herpes treatment market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
- Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Genital Herpes treatment market landscape.
- A detailed review of the Genital Herpes treatment market, historical and forecasted Genital Herpes market size, Genital Herpes market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The Genital Herpes treatment market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Genital Herpes therapeutics market.
Genital Herpes Therapeutics Market Report Insights
- Genital Herpes Patient Population
- Genital Herpes Therapeutic Approaches
- Genital Herpes Pipeline Analysis
- Genital Herpes Market Size
- Genital Herpes Market Trends
- Existing and Future Genital Herpes Therapeutics Market Opportunity
Genital Herpes Therapeutics Market Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Genital Herpes Epidemiology Segmentation
- Inclusion of Country specific treatment guidelines
- KOL’s feedback on approved and emerging Genital Herpes therapies
- Key Cross Competition
- Genital Herpes Conjoint analysis
- Genital Herpes Drugs Uptake
- Key Genital Herpes Market Forecast Assumptions
Genital Herpes Therapeutics Market Report Assessment
- Current Genital Herpes Treatment Practices
- Genital Herpes Unmet Needs
- Genital Herpes Pipeline Product Profiles
- Genital Herpes Therapeutics Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
FAQs
- What is the growth rate of the 7MM Genital Herpes treatment market?
- What was the Genital Herpes market size, the Genital Herpes market size by therapies, Genital Herpes market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
- What are the pricing variations among different geographies for approved and off-label Genital Herpes therapies?
- How would the Genital Herpes market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
- What are the current and emerging options for the Genital Herpes treatment?
- How many companies are developing therapies for the Genital Herpes treatment?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing Genital Herpes therapies?
Reasons to buy
- The Genital Herpes therapeutics market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Genital Herpes Drugs Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
- Understand the existing Genital Herpes therapeutics market opportunities in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the Genital Herpes therapeutics market will help devise strategies to help get ahead of competitors.
- Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the Genital Herpes unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Click here to Read More about the Related Articles:-
